Mochi vs Medvi: GLP-1 Telehealth Genetic Testing

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Mochi and Medvi represent two distinct telehealth models for GLP-1 access, yet both face a common clinical question: which candidates benefit most from these medications, and can genetic or biomarker data improve selection? Recent surveys suggest approximately 40% of telehealth GLP-1 users report interest in genetic testing or metabolic profiling before starting therapy. Both platforms offer remote consultations, but their assessment depth and use of ancillary testing differ meaningfully.

Patients comparing Mochi versus Medvi often wonder whether one platform's screening approach yields better outcomes or safety profiles than the other. Mention Mochi or Medvi to a prospective patient, and the immediate concern is transparency: what does each platform evaluate, how long is the consultation, and does genetic or metabolic data influence their clinical recommendation? PlexusDx takes a precision-wellness stance, offering compounded peptides alongside optional genetic pathway insights—not to predict exact drug response, but to support more data-informed dialogue with a qualified healthcare provider about individual predispositions in GLP-1 and GIPR signaling pathways.

Mochi and Medvi: Platform Models and Clinical Scope

Mochi operates as a direct-to-consumer telehealth service emphasizing rapid GLP-1 access with streamlined physician consultations. The platform typically reviews medical history, current medications, and basic metabolic markers before issuing a prescription. Mochi's model prioritizes speed and convenience, targeting patients with established metabolic needs.

Medvi functions as a broader digital health ecosystem connecting patients to independent physicians and nurse practitioners for medication management. Medvi's consultations tend to be more comprehensive, including cardiovascular risk assessment, kidney function evaluation, and thyroid screening. Medvi positions itself as a deeper clinical alternative to quick-turnaround services, though consultation availability and wait times vary regionally.

Genetic Testing and Biomarker Differentiation

Neither Mochi nor Medvi currently offers integrated genetic pathway testing as standard practice. However, both platforms can refer patients to external genetic or metabolic testing if clinically indicated. This gap highlights an emerging market opportunity: patients increasingly seek biomarker context before committing to long-term peptide therapy.

Platform Element	Mochi Approach	Medvi Approach	PlexusDx Model
Consultation Type	Automated or brief physician review	Extended provider assessment	Supports patient education and provider referral
Genetic Testing	Not integrated; external referral only	Discretionary; provider-ordered	Optional Precision Peptide Genetic Test reveals peptide pathway predispositions
Biomarker Scope	Basic metabolic screening	Comprehensive metabolic and cardiovascular	Genetic pathway insights + provider-ordered labs
Medication Options	Limited to branded GLP-1 injectables	Branded and off-label agents	Compounded semaglutide, tirzepatide, and dual protocols

Clinical Evidence and Patient Selection Criteria

Both Mochi and Medvi screen for basic contraindications: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe kidney disease, and active pancreatitis. Medvi's more detailed questionnaire may catch additional risk factors such as diabetic retinopathy or gastroparesis. Research in Obesity Reviews (2023) suggests deeper pre-treatment assessment correlates with higher medication adherence and fewer adverse events.

Genetic predispositions in GLP1R, GIPR, and FTO genes may influence individual baseline weight, insulin sensitivity, and theoretical peptide responsiveness. A qualified provider interpreting genetic data alongside clinical history, BMI, comorbidities, and lifestyle factors creates a more holistic patient profile. Neither Mochi nor Medvi currently integrates such genetic context into their standard protocols, though Medvi's extended consultation may allow for individualized discussion if a patient brings external genetic results.

Safety Monitoring and Follow-Up Protocols

Mochi's streamlined model results in shorter initial consultations but may limit ongoing safety monitoring. The platform typically offers nurse support for side effect management and dosage adjustments. However, comprehensive follow-up labs and cardiovascular assessments remain the patient's responsibility in coordination with primary care.

Medvi positions follow-up as part of its broader platform experience, with provider check-ins scheduled at regular intervals and encouragement for concurrent primary care coordination. Medvi's approach reduces risk of unmonitored adverse events, particularly in patients with pre-existing hypertension, diabetes, or renal impairment. Both platforms require patients to disclose all medications and supplements; neither can replace ongoing communication with a primary care physician.

Genetic Pathway Insights and Precision Peptide Selection

PlexusDx recognizes that genetic variants in peptide signaling pathways—such as GLP1R rs6923761 and GIPR rs1800437—may help provide context for individual predispositions toward weight, appetite regulation, and metabolic function. The Precision Peptide Genetic Test identifies these variants to support more informed conversations with a qualified healthcare provider, not to guarantee medication response or clinical outcomes.

A patient comparing Mochi and Medvi might benefit from understanding their own genetic landscape before choosing a telehealth partner. If a genetic test reveals specific peptide pathway predispositions, that data can inform a discussion with Medvi's or any provider's clinical team about whether a particular GLP-1 agent, dosing strategy, or compounded formulation aligns with individual physiology. This is especially relevant for patients considering compounded peptides, where dosing flexibility and formulation choice may offer more personalization than branded alternatives.

PlexusDx supports this precision approach by offering the Precision Peptide Genetic Test as a standalone or add-on assessment. Results should be interpreted alongside clinical evaluation and metabolic markers by a qualified healthcare provider. The test does not predict exact medication response, contraindicate therapy, or replace medical judgment—rather, it can support a more data-informed decision-making conversation.

How PlexusDx Supports a More Personalized Approach

Patients investigating Mochi versus Medvi often ask which platform better personalizes care. PlexusDx takes a different approach: compounded peptides with optional genetic pathway insights. The Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R genes to reveal individual predispositions in peptide signaling—information that may help contextualize why one patient thrives on a GLP-1 agent while another tolerates it poorly. This genetic framework is not a guarantee of response; it is a supporting data point for conversations with a qualified provider.

The Precision Peptide Genetic Test ($99 as add-on or $298 standalone) decodes peptide pathway predispositions relevant to appetite, weight regulation, and metabolic response. Key variants analyzed include GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313. Unlike pharmacogenomic testing that predicts drug metabolism, this test focuses on genetic underpinnings of peptide pathway function, helping individuals and their providers understand baseline physiological tendencies.

Whether a patient chooses Mochi's rapid access, Medvi's comprehensive assessment, or a compounded peptide protocol through a telehealth partner, genetic and biomarker context can enrich the clinical conversation. PlexusDx enables patients to access compounded semaglutide, tirzepatide, or dual GLP-Squared protocols alongside optional genetic insights—empowering a more informed dialogue between patient and qualified healthcare provider about which peptide formulation and dosing strategy aligns with individual needs.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the key difference between Mochi and Medvi?

Mochi emphasizes rapid, streamlined telehealth GLP-1 access with shorter consultations. Medvi provides more comprehensive provider assessments, including detailed cardiovascular and metabolic screening. Medvi typically allows more time for clinical discussion and follow-up coordination.

Do Mochi or Medvi offer genetic testing as standard?

Neither platform integrates genetic testing as routine practice. Both may refer patients to external genetic evaluation if clinically indicated. PlexusDx offers optional Precision Peptide Genetic Testing to reveal peptide pathway predispositions, supporting informed conversations with healthcare providers.

How does genetic data inform GLP-1 selection?

Variants in GLP1R, GIPR, and FTO genes may reflect baseline predispositions toward weight, appetite sensitivity, and metabolic function. A qualified provider can interpret this genetic context alongside BMI, comorbidities, and clinical history to support personalized peptide choice—though genetic data does not predict exact medication response.

What are the main safety differences between these platforms?

Medvi's extended consultations may identify more pre-existing risk factors, reducing adverse event likelihood. Mochi offers nurse support but relies on patients to coordinate primary care follow-up. Both require ongoing communication with a primary care physician regardless of platform choice.

Does PlexusDx work with Mochi or Medvi?

PlexusDx operates independently, offering compounded semaglutide, tirzepatide, and GLP-Squared formulations through licensed 503A pharmacies. Patients may benefit from genetic pathway insights via Precision Peptide Genetic Test ($99 add-on, $298 standalone) to support conversations with any qualified provider about personalized peptide therapy.

How much does the Precision Peptide Genetic Test cost?

The Precision Peptide Genetic Test is available as a $99 add-on with any PlexusDx peptide product or $298 as a standalone assessment. Results reveal predispositions in peptide signaling pathways, not exact medication response, and should be interpreted with a qualified healthcare provider.

Mochi vs Medvi: Genetic Testing and GLP-1 Personalization

Mochi and Medvi are telehealth platforms offering GLP-1 medications with varying approaches to patient assessment and genetic testing.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →